Icneta 100 Capsule contains Itraconazole 100 mg, a broad-spectrum antifungal agent belonging to the triazole class. It is indicated for the treatment of various fungal infections, including aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and other systemic and superficial mycoses caused by susceptible fungi. Itraconazole works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. Icneta 100 Capsule is administered orally and exhibits good bioavailability when taken with food, enhancing absorption. It is metabolized primarily by the liver via the cytochrome P450 system, necessitating caution in patients with hepatic impairment and potential drug interactions with other medications metabolized by the same pathway. Common adverse effects include gastrointestinal disturbances such as nausea, vomiting, and abdominal pain, as well as headache and dizziness. Liver function tests should be monitored periodically during prolonged therapy due to the risk of hepatotoxicity. Icneta 100 Capsule should be used under medical supervision, with dosage adjustments based on the severity of infection and patient response. It is contraindicated in patients with known hypersensitivity to itraconazole or other azole antifungals.